Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028

医薬品リーダーシリーズ:世界の眼薬メーカー上位25社

◆タイトル:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028
◆商品コード:VGN808068
◆調査・発行会社:visiongain
◆発行日:2018年7月
◆ページ数:223
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)GBP2,699 ⇒換算¥410,248見積依頼/購入/質問フォーム
Five User(5名様閲覧用)GBP2,999 ⇒換算¥455,848見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)GBP4,999 ⇒換算¥759,848見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"医薬品リーダーシリーズ:世界の眼薬メーカー上位25社"について調査・分析し、レポートサマリー、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、主要企業分析、結論などの情報をお届けいたします。

The global ophthalmic drugs market was valued at $23bn in 2017. The market was dominated by the Retinal Disorder drug submarket which held 39.1% of the global ophthalmic drugs market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 223-page report you will receive 83 tables and 71 figures– all unavailable elsewhere.

The 223-page report provides clear detailed insight into the top ophthalmic drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Top 25 Ophthalmic Drug Manufacturers 2018-2028

Report Scope

• Global ophthalmic drugs market revenue forecasts from 2018-2028

• Global ophthalmic drugs market revenue orecasts from 2018-2028, by submarket:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
• Other Ophthalmic Drugs

• Revenue forecasts from 2018-2028 of the leading ophthalmic drugs:
• Alphagan
• Avastin
• Azopt
• Eylea
• Lucentis
• Lumigan & Ganfort
• Other Ophthalmic Drugs
• Restasis
• Vigamix
• Xalatan/Xalacom

• Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
• Acucela
• Akorn
• Alimera Sciences
• Allergan
• Amakem
• Bayer
• Chengdu Kanghong
• EyeGate Pharmaceuticals
• Gene Signal
• Icon Biosciences
• MacuCLEAR
• Neurotech
• Novartis
• Omeros
• Ophthotech
• Otsuka Pharmaceutical
• Pfizer
• pSivida Corp.
• Regeneron
• Roche
• Santen
• Senju
• Shire
• ThromboGenics
• Valeant

• Our report provides an overview, revenue forecast from 2018-2028 of the ophthalmic drugs segment, revenue forecast from 2018-2028 of the leading drugs, product pipeline and SWOT Analysis, for these companies:
• Akorn
• Alcon
• Allergan
• Bausch & Lomb
• Bayer
• Novartis
• Pfizer
• Regeneron
• Roche
• Santen
• Senju
• Valeant

• Our report provides these Qualitative Analysis:
• Drivers and Restraints of the Global Ophthalmic Drugs market
• SWOT Analysis of selected leading companies
• Porter’s Five Forces Analysis of the Global Ophthalmic Drugs Market

Visiongain’s study is intended for anyone requiring commercial analyses for the ophthalmic drugs market. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs.

【レポートの目次】

1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: Very Brief Overview
2.2 The Global Burden of Eye Disease
2.3 Ophthalmic Drugs: Market Segmentation
2.4 Glaucoma: the ‘Silent Thief of Sight’
2.4.1 A Classification of Glaucoma
2.4.2 Risk Factors for Glaucoma
2.4.3 Diagnosis of Glaucoma
2.4.4 Drug Treatment of Glaucoma
2.4.5 Laser Treatment and Surgery for Glaucoma
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry (Non-Exudative) AMD
2.5.2 Wet (Exudative) AMD
2.5.3 Risk Factors for AMD
2.5.4 Diagnosis of AMD
2.5.5 Treatment of AMD
2.6 Diabetic Retinopathy (DR)
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Treatment of Diabetic Retinopathy
2.7 Ocular Allergy and Allergic Conjunctivitis
2.7.1 Diagnosis of Ocular Allergy
2.7.2 Treatment of Ocular Allergy
2.8 Ocular Inflammatory Disease
2.8.1 Treatment of Ocular Inflammatory Disease
2.9 Eye Infections
2.9.1 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Treatment of Dry Eye Syndrome
2.11 Phases of Clinical Trials

3. Ophthalmic Drugs: World Market 2018-2028
3.1 The World Ophthalmic Drugs Market in 2018
3.2 World Ophthalmic Drugs Market: Sales Forecast 2018-2028
3.3 Leading Ophthalmic Drugs
3.4 Leading Companies in the Ophthalmic Drugs Market
3.4.1 Top 25 Ophthalmic Drug Manufacturers
3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2018-2028
3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2018-2028
3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2018-2028
3.5.3 Glaucoma Drugs Market: Sales Forecast 2018-2028
3.5.4 Dry Eye Drugs Market: Sales Forecast 2018-2028
3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2018-2028
3.6 How Will Market Shares Change to 2028?
3.7 World Ophthalmic Drugs Market: Drivers and Restraints 2018-2028
3.7.1 World Ophthalmic Drugs Market: Analysis of Drivers
3.7.2 World Ophthalmic Drugs Market: Analysis of Restraints

4. Leading US Ophthalmic Drug Manufacturers 2018-2028
4.1 Allergan Overview
4.1.1 Allergan: Ophthalmic Product Portfolio
4.1.2 Allergan: Late Stage Ophthalmic Product Pipeline
4.1.3 Allergan: Ophthalmic Revenue Forecast 2018-2028
4.1.4 Allergan: SWOT Analysis
4.2 Pfizer Overview
4.2.1 Pfizer: Ophthalmic Product Portfolio
4.2.2 Pfizer: Ophthalmic Product Pipeline
4.2.3 Pfizer: Revenue Forecast 2018-2028
4.2.4 Pfizer: SWOT Analysis
4.3 Regeneron Overview
4.3.1 Regeneron: Ophthalmic Product Portfolio
4.3.2 Regeneron: Ophthalmic Product Pipeline
4.3.3 Regeneron: Revenue Forecast 2018-2028
4.3.4 FDA Approves Zaltrap (aflibercept)
4.3.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
4.3.6 Regeneron: SWOT Analysis
4.4 Akorn Overview
4.4.1 Akorn: Ophthalmic Product Portfolio
4.4.2 Akorn: Revenue Forecast 2018-2028
4.4.3 Akorn: SWOT Analysis

5. Leading European Ophthalmic Drug Manufacturers 2018-2028
5.1 Bayer Overview
5.1.1 Bayer: Ophthalmic Product Pipeline
5.1.2 Eylea: non-US Sales Forecast 2018-2028
5.1.3 Bayer: Revenue Forecast 2018-2028
5.2 Novartis (including Alcon) Overview
5.2.1 Novartis: Ophthalmic Product Portfolio
5.2.2 Novartis: Ophthalmic Product Pipeline
5.2.3 Novartis: Revenue Forecast 2018-2028
5.2.4 Novartis: SWOT Analysis
5.3 Roche Overview
5.3.1 Roche: Ophthalmic Product Portfolio
5.3.2 Roche: Ophthalmic Product Pipeline
5.3.3 Roche: Revenue Forecast 2018-2028
5.3.4 Roche: SWOT Analysis

6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2018-2028
6.1 Santen Overview
6.1.1 Santen: Ophthalmic Product Portfolio
6.1.2 Santen: Ophthalmic Product Pipeline
6.1.3 Santen: Revenue Forecast 2018-2028
6.1.4 Santen: SWOT Analysis
6.2 Senju Overview
6.2.1 Senju: Ophthalmic Product Portfolio
6.2.2 Senju: Ophthalmic Product Pipeline
6.2.3 Senju: Revenue Forecast 2018-2028
6.2.4 Senju: SWOT Analysis
6.3 Valeant Overview
6.3.1 Valeant: Ophthalmic Product Portfolio
6.3.2 Valeant: Ophthalmic Product Pipeline
6.3.3 Valeant: Revenue Forecast 2018-2028
6.3.4 Valeant: SWOT Analysis

7. Emerging Ophthalmic Drug Manufacturers in 2017
7.1 Companies with Small Ophthalmic Portfolios and Promising Pipeline Candidates, 2017
7.2 Acucela
7.3 Aerie Pharmaceuticals
7.4 Aerpio Therapeutics: Developing AKB 9778
7.5 Alimera Sciences
7.5.1 Iluvien: Increasing Geographical Reach and Increasing Sales
7.5.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
7.6 Amakem
7.7 Ampio Pharmaceuticals
7.8 Chengdu Kanghong Pharmaceutical
7.9 Eleven Biotherapeutics
7.10 EyeGate Pharmaceuticals
7.11 Gene Signal
7.11.1 Aganirsen: Preventing Corneal Graft Rejection
7.12 Icon Bioscience
7.13 MacuCLEAR
7.13.1 MC 1101: a Potential Therapy for Dry AMD
7.14 Neurotech
7.15 Omeros
7.16 OphthaliX (Can-Fite BioPharma)
7.17 Ophthotech
7.17.1 Fovista: Potential Game-Changer in AMD
7.17.2 Fovista: Significant Improvement on Lucentis in Phase II Trials
7.17.3 Zimura: Complement C5 Inhibitor
7.18 Otsuka Pharmaceutical
7.19 pSivida Corp.
7.20 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
7.21 Shire
7.21.1 Lifitegrast (SHP606) for Dry Eye
7.21.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity
7.22 ThromboGenics
7.22.1 Jetrea (ocriplasmin)
7.22.2 ThromboGgenics: Leading Diabetic Eye Disease Pipeline

8. Qualitative Analysis of the Ophthalmic Drugs Market 2018-2028
8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
8.1.1 Rivalry Among Competitors [Medium]
8.1.2 Threat of New Entrants [Low]
8.1.3 Power of Suppliers [Low]
8.1.4 Power of Buyers [Medium]
8.1.5 Threat of Substitutes [Medium]

9. Conclusions
9.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
9.2 The World Ophthalmic Drugs Market in 2017
9.2.1 Leading Ophthalmic Drugs Market Segments
9.2.2 Leading Ophthalmic Drugs
9.2.3 Leading Ophthalmic Drugs Companies
9.3 World Ophthalmic Drugs Market Forecast 2018-2028
9.4 The Future of the Ophthalmic Drugs Market?
9.4.1 Increasing Revenue Concentration among Specialist Companies
9.4.2 The Rise of Generics
9.4.3 Small Companies Can Have a Big Impact
9.4.4 What Will Succeed in the Ophthalmic Drugs Market?

Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Tables
Table 2.1 ICD 10 Classification of Visual Impairment, 2015
Table 2.2 Drug Treatments for Glaucoma, 2017
Table 2.3 Drug Treatments for AMD, 2017
Table 2.4 Drug Treatments for Ocular Allergy, 2017
Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2017
Table 2.6 Selected Drug Treatments for Eye Infections, 2017
Table 2.7 Clinical Trial Phases
Table 3.1 World Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2017
Table 3.2 World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2028
Table 3.3 Top 10 Ophthalmic Drugs: Revenue ($m), Market Share (%), Rank, Active Ingredient and Manufacturer, 2017
Table 3.4 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Market Share (%), 2017
Table 3.5 Top 25 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2017
Table 3.6 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2017-2028
Table 3.7 Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2028
Table 3.8 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 3.9 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2028
Table 3.10 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2028
Table 3.11 Other Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2028
Table 3.12 Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2017, 2023 and 2028
Table 4.1 Allergan: Overview, 2017
Table 4.2 Allergan: Ophthalmic Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
Table 4.3 Allergan: Restasis Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.4 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.5 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.6 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.7 Allergan: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 4.8 Allergan: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 4.9 Pfizer: Overview, 2017
Table 4.10 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.11 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.12 Pfizer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 4.13 Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 4.14 Regeneron: Overview, 2017
Table 4.15 Regeneron: Eylea Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.16 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.17 Regeneron: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 4.18 Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 4.19 Akorn: Overview, 2017
Table 4.20 Akorn: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 4.21 Akorn: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 4.22 Akorn: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 5.1 Bayer: Overview, 2017
Table 5.2 Bayer: Eylea Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.3 Bayer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.4 Bayer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 5.5 Novartis: Overview, 2017
Table 5.6 Novartis: Lucentis Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.7 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.8 Novartis: Vigamox Revenue ($m), AGR (%) and CAGR(%), 2017-2028
Table 5.9 Novartis: Azopt Revenue ($m), AGR (%) and CAGR(%), 2017-2028
Table 5.11 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.12 Novartis: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 5.13 Novartis: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 5.14 Roche: Overview, 2017
Table 5.15 Roche: Lucentis Revenue ($m), AGR (%) and CAGR(%), 2017-2028
Table 5.16 Roche: Avastin Ophthalmic Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.17 Roche: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 5.18 Roche: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 5.19 Roche: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 6.1 Santen: Overview, 2017
Table 6.2 Santen: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Date, Region, 2017
Table 6.3 Santen: Eylea Revenue ($m), AGR (%) and CAGR(%), 2017-2028
Table 6.4 Santen: Hyalein Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.5 Santen: Cosopt Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.6 Santen: Tapros/Taflotan Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.7 Santen: Diquas Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.8 Santen: Cravit Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.9 Santen: Alesion Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.10 Santen: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.11 Santen: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 6.12 Santen: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 6.13 Senju: Overview, 2017
Table 6.14 Senju: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Year, 2017
Table 6.15 Senju: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.16 Senju: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 6.17 Senju: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 6.18 Valeant: Overview, 2017
Table 6.19 Valeant: Lotemax Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.20 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
Table 6.21 Valeant: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
Table 6.22 Valeant: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
Table 7.1 Otsuka Pharmaceutical: Overview of Ophthalmic Drug Pipelines, Drug Type, Indication, Country
Table 9.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), Market Share (%), 2018

List of Figures
Figure 1.1 Global Causes of Visual Impairment (% of cases), 2017
Figure 1.2 World 65+ Population Forecast: Size (millions), CAGR (%), by National Market, 2015 and 2026
Figure 1.3 Global Ophthalmic Drugs Market Segmentation Overview, 2017
Figure 2.1 Estimated Global Blindness and Visual Impairment (% of people), 2015
Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2015
Figure 2.3 Global Causes of Visual Impairment (% of cases), 2015
Figure 2.4 Global Causes of Blindness (% of cases), 2015
Figure 2.5 Classification of Glaucoma, 2017
Figure 3.1 World Ophthalmic Drugs Market: Revenues ($m) by Segment, 2017
Figure 3.2 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2017
Figure 3.3 World Ophthalmic Drugs Market Forecast: Revenue ($m) and AGR (%), 2018-2028
Figure 3.4 Top 9 Ophthalmic Drugs: Revenues ($m), 2017
Figure 3.5 Top 9 Ophthalmic Drugs: Market Share (%), 2017
Figure 3.6 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenues ($m), 2017
Figure 3.7 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2017
Figure 3.8 Retinal Disorders Drugs Market Forecast: Revenues ($m), 2017-2028
Figure 3.9 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), 2017-2028
Figure 3.10 Glaucoma Drugs Market Forecast: Revenues ($m), 2017-2028
Figure 3.11 Dry Eye Drugs Market Forecast: Revenues ($m), 2017-2028
Figure 3.12 Other Ophthalmic Drugs Market Forecast: Revenues ($m), 2017-2028
Figure 3.13 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2017
Figure 3.14 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2023
Figure 3.15 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2028
Figure 3.16 World Ophthalmic Drugs Market: Drivers and Restraints, 2018-2028
Figure 4.1 Allergan: Restasis Revenue ($m) and AGR (%), 2017-2028
Figure 4.2 Allergan: Lumigan and Ganfort Revenue ($m) and AGR (%), 2017-2028
Figure 4.3 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m) and AGR (%), 2017-2028
Figure 4.4 Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
Figure 4.5 Allergan: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
Figure 4.6 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), 2017-2028
Figure 4.7 Pfizer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
Figure 4.8 Pfizer: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
Figure 4.9 Regeneron: Eylea Revenue ($m) and AGR (%), 2017-2028
Figure 4.10 Regeneron: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
Figure 4.11 Regeneron: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
Figure 4.12 Akorn: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
Figure 4.13 Akorn: Ophthalmic Drugs Market Share (%), 2017-2028
Figure 5.1 Bayer: Eylea Revenue ($m) and AGR (%), 2017-2028
Figure 5.2 Bayer: Ophthalmic Drugs Revenue ($m) and AGR(%), 2017-2028
Figure 5.3 Bayer: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
Figure 5.4 Novartis: Lucentis Revenue ($m) and AGR(%), 2017-2028
Figure 5.5 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m) and AGR (%), 2017-2028
Figure 5.6 Novartis: Vigamox Revenue ($m) and AGR(%), 2017-2028
Figure 5.7 Novartis: Azopt Revenue ($m) and AGR (%), 2017-2028
Figure 5.8 Novartis: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
Figure 5.9 Novartis: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
Figure 5.10 Roche: Lucentis Revenue ($m) and AGR (%), 2017-2028
Figure 5.11 Roche: Avastin Ophthalmic Revenue ($m) and AGR(%), 2017-2028
Figure 5.12 Roche: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
Figure 5.13 Roche: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2017
Figure 6.2 Santen: Major Prescription Ophthalmic Drugs, Revenue Share (%), FY 2017
Figure 6.3 Santen: Eylea Revenue ($m) and AGR (%), 2017-2028
Figure 6.4 Santen: Hyalein Revenue ($m) and AGR (%), 2017-2028
Figure 6.5 Santen: Cosopt Revenue ($m) and AGR (%), 2017-2028
Figure 6.6 Santen: Tapros/Taflotan Revenue ($m) and AGR (%), 2017-2028
Figure 6.7 Santen: Diquas Revenue ($m) and AGR (%), 2017-2028
Figure 6.8 Santen: Cravit Revenue ($m) and AGR (%), 2017-2028
Figure 6.9 Santen: Alesion Revenue ($m) and AGR (%), 2017-2028
Figure 6.10 Santen: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
Figure 6.11 Santen: Ophthalmic Drugs Market Share (%), 2017-2028
Figure 6.12 Senju: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
Figure 6.13 Senju: Ophthalmic Drugs Market Share (%), 2017-2028
Figure 6.14 Valeant: Lotemax Revenue ($m) and AGR (%), 2017-2028
Figure 6.15 Valeant: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
Figure 6.16 Valeant: Ophthalmic Drugs Market Share (%), 2017-2028
Figure 7.1 Gene Signal: Ophthalmic Drug Pipeline Progress
Figure 7.2 Ophthotech: Ophthalmic Drug Pipeline Progress
Figure 7.3 Otsuka Pharmaceutical: Ophthalmic Drug Pipeline Progress
Figure 7.4 Shire: Ophthalmic Drug Pipeline Progress
Figure 8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market, 2018-2028

★調査レポート[医薬品リーダーシリーズ:世界の眼薬メーカー上位25社] ( Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028 / VGN808068) 販売に関する免責事項
[医薬品リーダーシリーズ:世界の眼薬メーカー上位25社] ( Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028 / VGN808068) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆